Aytu BioPharma, Inc.AYTUNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2025-8.93%
2024-40.01%
20230.28%
202225.22%
202179.68%
202061.44%
20198.50%
20180.71%
201799.51%
2016101.37%